Physicians' Academy for Cardiovascular Education

LDL-receptor expression correlates with the reduction in LDL-c in patients with homozygous FH on PCSK9 inhibitor treatment

Homozygous Familial Hypercholesterolemia Patients With Identical Mutations Variably Express the LDLR (Low-Density Lipoprotein Receptor) Implications for the Efficacy of Evolocumab

Literature - Thedrez A, Blom DJ, Ramin-Mangata S, et al. - Arterioscler Thromb Vasc Biol. 2017;published online ahead of print

Main results

Conclusion

//Ex vivo// LDLR expression is inversely associated with the plasma levels of LDL-c and apoB in HoFH patients. Residual LDLR expression seems to drive the individual response to evolocumab in these patients.

References

Show references

Find this article online at Arterioscler Thromb Vasc Biol

Share this page with your colleagues and friends: